Goldman Sachs, Leerink, Piper Sandler and Truist are acting as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KROS:
- Keros Therapeutics Announces Proposed Public Offering of Common Stock
- Keros Therapeutics price target lowered by $25 at BTIG, here’s why
- Keros says signaling by KER-050 demonstrated potential to treat myelofibrosis
- Keros Therapeutics says KER-050 treatment reduced iron overload
- Keros Therapeutics presents clinical data from KER-050 program
